Cargando…
Leptin, Both Bad and Good Actor in Cancer
Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and l...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235379/ https://www.ncbi.nlm.nih.gov/pubmed/34202969 http://dx.doi.org/10.3390/biom11060913 |
_version_ | 1783714303710330880 |
---|---|
author | Jiménez-Cortegana, Carlos López-Saavedra, Ana Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Castiñeiras, Jesús Virizuela-Echaburu, Juan A. de la Cruz-Merino, Luis Sánchez-Margalet, Víctor |
author_facet | Jiménez-Cortegana, Carlos López-Saavedra, Ana Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Castiñeiras, Jesús Virizuela-Echaburu, Juan A. de la Cruz-Merino, Luis Sánchez-Margalet, Víctor |
author_sort | Jiménez-Cortegana, Carlos |
collection | PubMed |
description | Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the “obesity paradox”, and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology. |
format | Online Article Text |
id | pubmed-8235379 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-82353792021-06-27 Leptin, Both Bad and Good Actor in Cancer Jiménez-Cortegana, Carlos López-Saavedra, Ana Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Castiñeiras, Jesús Virizuela-Echaburu, Juan A. de la Cruz-Merino, Luis Sánchez-Margalet, Víctor Biomolecules Review Leptin is an important regulator of basal metabolism and food intake, with a pivotal role in obesity. Leptin exerts many different actions on various tissues and systems, including cancer, and is considered as a linkage between metabolism and the immune system. During the last decades, obesity and leptin have been associated with the initiation, proliferation and progression of many types of cancer. Obesity is also linked with complications and mortality, irrespective of the therapy used, affecting clinical outcomes. However, some evidence has suggested its beneficial role, called the “obesity paradox”, and the possible antitumoral role of leptin. Recent data regarding the immunotherapy of cancer have revealed that overweight leads to a more effective response and leptin may probably be involved in this beneficial process. Since leptin is a positive modulator of both the innate and the adaptive immune system, it may contribute to the increased immune response stimulated by immunotherapy in cancer patients and may be proposed as a good actor in cancer. Our purpose is to review this dual role of leptin in cancer, as well as trying to clarify the future perspectives of this adipokine, which further highlights its importance as a cornerstone of the immunometabolism in oncology. MDPI 2021-06-20 /pmc/articles/PMC8235379/ /pubmed/34202969 http://dx.doi.org/10.3390/biom11060913 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jiménez-Cortegana, Carlos López-Saavedra, Ana Sánchez-Jiménez, Flora Pérez-Pérez, Antonio Castiñeiras, Jesús Virizuela-Echaburu, Juan A. de la Cruz-Merino, Luis Sánchez-Margalet, Víctor Leptin, Both Bad and Good Actor in Cancer |
title | Leptin, Both Bad and Good Actor in Cancer |
title_full | Leptin, Both Bad and Good Actor in Cancer |
title_fullStr | Leptin, Both Bad and Good Actor in Cancer |
title_full_unstemmed | Leptin, Both Bad and Good Actor in Cancer |
title_short | Leptin, Both Bad and Good Actor in Cancer |
title_sort | leptin, both bad and good actor in cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235379/ https://www.ncbi.nlm.nih.gov/pubmed/34202969 http://dx.doi.org/10.3390/biom11060913 |
work_keys_str_mv | AT jimenezcorteganacarlos leptinbothbadandgoodactorincancer AT lopezsaavedraana leptinbothbadandgoodactorincancer AT sanchezjimenezflora leptinbothbadandgoodactorincancer AT perezperezantonio leptinbothbadandgoodactorincancer AT castineirasjesus leptinbothbadandgoodactorincancer AT virizuelaechaburujuana leptinbothbadandgoodactorincancer AT delacruzmerinoluis leptinbothbadandgoodactorincancer AT sanchezmargaletvictor leptinbothbadandgoodactorincancer |